The pharmaceutical company has raised over $100m in equity funding from investors including Boehringer Ingelheim and Allergen.
US-based pharmaceutical company Vitae Pharmaceuticals filed for an initial public offering on Tuesday that could raise up to $55m.
Viate’s shareholders include pharmaceutical companies Boehringer Ingelheim International, which holds a 10.8% stake in the company, and Allergen, which owns 5.6%. The largest shareholders are venture capital firms Prospect Venture Partners (23.3%), New Enterprise Associates (17.8%), Venrock (15.6%) and Atlas Venture (11.2%).
Founded in 2001, Vitae is developing small molecule drugs for diseases including type diabetes and Alzheimer’s. The proceeds will…